CVS Caremark Wegovy Coverage: When the PBM Says Yes (and When It Says No)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · As of May 2026, confirm directly with your plan

Key Takeaways

• CVS Caremark is the PBM for Aetna and many large self-funded and commercial plans
• 2024 formulary realignments moved Wegovy to preferred status on some Caremark templates, with corresponding changes to Zepbound positioning
• Standard Caremark PA requires BMI 30+ or BMI 27+ with comorbidities, plus structured weight-management documentation
• The March 2024 FDA cardiovascular indication created an alternative coverage pathway for members with established heart disease
• Self-funded ERISA employer plans can exclude anti-obesity medications entirely, regardless of Caremark's standard template

Direct answer

Many CVS Caremark formulary templates cover Wegovy with prior authorization as of May 2026. The 2024 formulary realignment moved Wegovy to preferred status on certain Caremark templates. Coverage depends on the specific employer plan contract that uses Caremark as PBM. Self-funded plans can exclude the category. The March 2024 cardiovascular indication offers an alternative path for members with established heart disease.

Table of contents

1. CVS Caremark's role in pharmacy benefits
2. The 2024 Wegovy formulary realignment
3. Standard Caremark PA criteria for Wegovy
4. The cardiovascular indication pathway
5. How to identify your Caremark template
6. Cost scenarios across plan types
7. The Aetna connection
8. Self-funded ERISA exclusions
9. Appealing a denial
10. The compounded semaglutide question
11. Decision framework
12. FAQ
13. Sources

CVS Caremark's role in pharmacy benefits

CVS Caremark is one of the three largest pharmacy benefit managers in the United States. The PBM is owned by CVS Health, which also owns Aetna and the CVS retail pharmacy chain. Caremark administers pharmacy benefits for plans that contract with it, including:

• Aetna (in-house affiliate)
• Many large self-funded employer plans
• Various commercial insurers contracting with Caremark
• State employee health plans in some jurisdictions
• Medicare Part D plans operated by Aetna and partner organizations

The PBM negotiates pricing and rebates with manufacturers, creates formulary templates, processes prior authorizations, and operates specialty pharmacy fulfillment. It does not bear insurance risk; the underlying plan does.

The 2024 Wegovy formulary realignment

In 2024, CVS Caremark announced significant changes to GLP-1 formulary placement that affected millions of covered members. Trade press reporting described shifts in preferred status between Wegovy and Zepbound for the obesity indication on certain Caremark templates.

The realignment reflected:

• Manufacturer rebate negotiations between Caremark, Novo Nordisk, and Eli Lilly
• Strategic positioning by both manufacturers competing for PBM preferred status
• Ongoing supply considerations (semaglutide moved off shortage status in October 2024)
• Clinical evidence accumulating from SELECT and SURMOUNT trials

For members affected by the changes:

• New Wegovy prescriptions face fewer step-therapy barriers on templates that elevated Wegovy
• Existing Zepbound users on affected templates faced potential switch pressure
• The opposite occurred on different templates that preferred Zepbound

Caremark's specific template assignments are not always transparent to members. Asking your employer's benefits team or calling Caremark member services for your specific plan provides the clearest answer.

Standard Caremark PA criteria for Wegovy

When Wegovy is covered (rather than excluded), Caremark PA typically requires:

1. BMI 30 or higher, or BMI 27 with documented weight-related comorbidity
2. Participation in a structured lifestyle modification program, typically 3 to 6 months of documented engagement
3. Demonstration of medical necessity
4. Absence of contraindications including personal or family history of medullary thyroid carcinoma or MEN 2
5. For step-therapy plans, prior trial of preferred alternative

Initial approval is typically 6 months. Continuation requires documented weight loss of at least 5% from baseline, demonstrating clinical response justifying continued therapy.

Patients not meeting the 5% threshold at reauthorization may have therapy discontinued. The trial extension data from STEP 4 (Rubino et al., JAMA 2021) demonstrates that continuing therapy supports maintained weight loss, while discontinuation produces regain. This creates a tension for members who plateaued near but not at the 5% threshold.

The cardiovascular indication pathway

The March 2024 FDA approval of Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity opened a parallel coverage pathway. The approval was based on the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), enrolling 17,604 patients with established cardiovascular disease.

SELECT demonstrated a 20% relative reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) over a mean follow-up of 39.8 months.

For Caremark members with established heart disease, the CV indication provides an alternative pathway. Even on plans that exclude anti-obesity drugs, the CV indication is typically reimbursable as cardiovascular care.

Caremark PA for the CV indication generally requires:

• Documented atherosclerotic cardiovascular disease (prior MI, prior stroke, or angiographically confirmed CAD)
• BMI 27 or higher
• Cardiology consultation or co-signature on the prescription
• Sometimes, documented statin therapy and other cardiovascular medications

How to identify your Caremark template

Caremark operates multiple formulary templates with different GLP-1 positions. To identify yours:

1. Check your insurance card for plan/group identifiers
2. Log in to caremark.com and use the formulary lookup tool
3. Request a Summary Plan Description (SPD) or Evidence of Coverage (EOC) from your employer or insurer
4. Call Caremark member services using the number on your card
5. Ask your prescriber's office to verify formulary status before submitting PA

The template determines which GLP-1 medications are preferred, what step therapy applies, and what PA criteria your specific plan uses.

Cost scenarios across plan types

Scenario	Approximate monthly cost
Covered, tier 2 commercial	$25 to $50
Covered, tier 3 commercial	$50 to $100
Covered, specialty tier	$100 to $300
With WeGoTogether copay card	As low as $25 (commercial only, eligibility-limited)
Uncovered retail cash	Approximately $1,350
NovoCare direct-pay	Approximately $499
Medicare Part D covered, CV indication	$2,000 annual cap applies

The Novo Nordisk WeGoTogether copay card is restricted to commercially insured patients with Wegovy coverage. Government insurance members (Medicare, Medicaid, Tricare) are not eligible. Current terms should be verified at enrollment.

The Aetna connection

Aetna uses Caremark as its in-house PBM. Aetna formulary decisions are made by Aetna's Pharmacy and Therapeutics Committee but executed through Caremark's pharmacy benefit infrastructure. The two operate as coordinated but distinct entities within CVS Health.

For Aetna members, Wegovy coverage tracks closely with Caremark's standard templates plus Aetna-specific adjustments. Most Aetna commercial plans follow the Caremark formulary preferences with similar PA criteria.

The Aetna-Caremark integration means coverage policy changes often propagate quickly across both Aetna and other Caremark-administered plans, though employer-specific contracts can produce variation.

Self-funded ERISA exclusions

Roughly 65% of employer-covered Americans are in self-funded plans, per Kaiser Family Foundation data. In self-funded plans, the employer (not the insurer) bears the financial risk. The employer designs the benefit, including whether anti-obesity medications are covered.

If your employer's SPD excludes anti-obesity medications as a category, Caremark cannot override that exclusion through prior authorization. The PBM administers the benefit per the employer's contract terms; it does not design coverage independently.

Members in plans that exclude obesity drugs have several options:

• Pursue the cardiovascular indication if applicable
• Advocate with HR for benefit expansion (some employers have added obesity coverage in 2024-2025)
• Use NovoCare direct-pay or out-of-pocket alternatives
• Consider compounded semaglutide as a separate category (different regulatory status, different product)

Appealing a denial

Caremark denial appeals follow plan-type-specific procedures:

Fully insured commercial: Internal Caremark appeal, peer-to-peer review, state IRO external review.

ERISA self-funded: Internal Caremark appeals per plan procedures, federal court review under ERISA.

Medicare Part D: CMS five-level appeals process.

Strategy for appeals:

• Submit complete clinical documentation
• Cite FDA approvals explicitly (March 2024 CV indication, December 2024 OSA for Zepbound)
• For CV indication: include cardiology documentation and SELECT trial citation
• Request peer-to-peer review before formal appeal
• Track deadlines carefully

The compounded semaglutide question

During the 2022-2024 semaglutide shortage, many patients used compounded semaglutide from telehealth platforms as an alternative to Wegovy. The FDA declared the shortage resolved in October 2024, triggering enforcement against many compounders.

As of May 2026, compounded semaglutide remains available through some 503A pharmacies operating under personalization exceptions (different dosing, oral or sublingual routes, combinations with additional ingredients).

Key distinctions:

• Compounded semaglutide is not Wegovy. Different product. Different regulatory status
• Compounded products are not FDA-approved
• CVS Caremark does not cover compounded medications
• The SELECT cardiovascular outcomes data applies to FDA-approved Wegovy, not to compounded preparations

Decision framework

If Wegovy is preferred on your Caremark template: Submit standard PA with BMI documentation, comorbidity evidence, and lifestyle modification participation.

If Wegovy is non-preferred or step-therapy: Either start with the preferred alternative or pursue step-therapy override with clinical rationale.

If your plan excludes anti-obesity drugs: Explore the CV indication if applicable. Consider NovoCare for out-of-pocket option. Advocate with HR.

If you have established cardiovascular disease: Pursue the CV indication separately from obesity criteria. This pathway often succeeds where obesity-only requests fail.

If you've been denied: Request peer-to-peer review first. File formal appeals. Use external review for fully insured plans or federal pathway for ERISA plans.

FAQ

Does CVS Caremark cover Wegovy? Many templates do, with PA. Plan-specific.

Why did CVS Caremark prefer Wegovy in 2024? Rebate negotiations and competitive positioning between manufacturers.

What is the prior authorization for Wegovy at CVS Caremark? BMI 30+ or BMI 27+ with comorbidities, lifestyle modification documentation.

How much does Wegovy cost with CVS Caremark? Covered: $25 to $300. With copay card: as low as $25. Uncovered: $1,350 retail or $499 NovoCare.

Does CVS Caremark cover Wegovy for heart disease? Coverage for the CV indication has expanded since March 2024.

Will my Caremark plan cover Wegovy if my employer excludes obesity drugs? Not under obesity indication. CV indication may apply for eligible members.

What is the appeals process? Plan-type-specific; internal then external review.

What if I'm moved from Wegovy to Zepbound or vice versa? New prescription required; not automatic. Step-therapy override available with clinical documentation.

Sources

1. FDA, Wegovy (semaglutide) prescribing information, cardiovascular risk reduction indication, March 2024
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. November 2023
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021
5. CVS Caremark Standard Control Formulary, 2026 plan year
6. CVS Health 2024 PBM formulary changes announcements, trade press coverage
7. Kaiser Family Foundation, Employer Health Benefits Survey, 2024 edition
8. Novo Nordisk, WeGoTogether Savings Card terms and conditions, 2025-2026
9. Novo Nordisk, NovoCare direct-pay program, 2025-2026
10. Aetna Pharmacy Benefit Guide, 2026
11. FDA Drug Shortages database, semaglutide status changes 2022-2024
12. ERISA appeals procedures, US Department of Labor

Footer disclaimers

Platform Disclaimer. FormBlends provides telehealth access to licensed clinicians and 503A compounding pharmacy partners. FormBlends has no relationship with CVS Caremark, CVS Health, Aetna, Novo Nordisk, or any insurer. Coverage data reflects publicly available information as of May 2026 and is subject to change.

Compounded Medication Notice. Compounded semaglutide prepared by 503A pharmacies is a different product than FDA-approved Wegovy. Compounded medications are not FDA-approved, not therapeutically equivalent to brand Wegovy, and not interchangeable.

Results Disclaimer. Weight loss and cardiovascular outcomes from clinical trials reflect average effects in study populations. Individual response varies by adherence, dose tolerability, and baseline metabolic status.

Trademark Notice. Wegovy is a registered trademark of Novo Nordisk A/S. CVS Caremark, Aetna, and CVS Health are registered marks of CVS Health Corporation. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. References are informational.